Bioactive Peptide Claims: Absorption and Metabolism

Step 1: Survival in digestion

Once eaten, peptides meet stomach acid and digestive enzymes. A 2020 review says peptides need to resist digestive enzymes during passage through the gut and cross the intestinal barrier intact and active to exert effects. [1] This is one reason test-tube findings often fail to carry over to people. See digestion and peptide formation.

Step 2: Crossing the intestinal lining

A 2024 review describes biochemical and physical barriers (pH changes, enzymes, the unstirred water layer, mucus and intestinal cells) and four entry routes: carrier-mediated transport, endocytosis, passing between cells and passive diffusion. How well a peptide crosses depends on its structure and on coexisting substances. [2] Di- and tripeptides can use the PepT1 transporter, [3] but their oral bioavailability is still described as limited. [3] A 2022 review adds that size, length, charge, hydrophobicity and amino acid sequence are critical for bioavailability. [4]

Step 3: Reaching the target and doing something

Even when a peptide gets into blood, it may be broken down or cleared quickly, or reach too little of the tissue to matter. A 2026 review of natural bioactive peptides reports that most unmodified natural peptides show low permeability and short half-lives in the experiments it covers, and that limited human pharmacokinetic evidence is a critical gap. [5]

A worked example is collagen: a review of collagen hydrolysate reports that small collagen pieces reach the blood, but it is not established that they act on the receptors engaged by larger fragments in laboratory studies. [6] See collagen and dietary peptides.

Step 4: Changing a real health outcome

This is where claims most often break down. The 2020 review says that although peptides show benefits in biochemical assays, cell cultures and animal models, translating them into practical uses is delayed because test-tube findings do not correlate with effects in the body, partly due to low bioavailability. [1] A 2026 review of peptide-based functional foods describes a significant disconnect between preliminary bioactivity data and demonstrable clinical efficacy. [7]

A real example: milk lactotripeptides inhibit an enzyme in the lab, and pooled trials found a small average blood-pressure reduction, yet a well-designed randomized trial found none. [8] [9] See milk-derived peptides.

How to read a claim

• "Contains bioactive peptides." This describes a test result. Ask: tested in people, at what amount, for what outcome?
• "Clinically proven." Ask for the trial: population, size, comparator, duration, whether the outcome was a blood test or a health event, and who paid for it.
• "Absorbed." Absorbed as intact peptide or as amino acids? Peptide in the blood is not the same as benefit.
• Biomarker versus outcome. A lower after-meal glucose reading is a biomarker. Fewer complications is an outcome.
• Food versus extract. A study of an extract does not show the same effect from the food. See food research vs concentrated products.

Regulators expect human evidence: a review notes human studies are essential for approval as a healthy food and to prevent false promises to consumers. [4] See how to evaluate peptide claims and mechanisms vs demonstrated clinical benefits.